These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16441244)

  • 1. Patient satisfaction with an injection device for multiple sclerosis treatment.
    Cramer JA; Cuffel BJ; Divan V; Al-Sabbagh A; Glassman M
    Acta Neurol Scand; 2006 Mar; 113(3):156-62. PubMed ID: 16441244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
    Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis.
    Jaber A; Bozzato GB; Vedrine L; Prais WA; Berube J; Laurent PE
    BMC Neurol; 2008 Oct; 8():38. PubMed ID: 18845005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon beta-1A: new preparation. A short-term impact on the course of multiple sclerosis.
    Prescrire Int; 1998 Oct; 7(37):142-3. PubMed ID: 10915418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b.
    Baum K; O'Leary C; Coret Ferrer F; Klímová E; Procházková L; Bugge J;
    Mult Scler; 2007 Nov; 13(9):1153-60. PubMed ID: 17967843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Panniculitis after subcutaneous injection of interferon beta in a multiple sclerosis patient.
    Heinzerling L; Dummer R; Burg G; Schmid-Grendelmeier P
    Eur J Dermatol; 2002; 12(2):194-7. PubMed ID: 11872423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
    Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
    Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cultural adaptation and validation of a peninsular Spanish version of the MSTCQ
    Muntéis Olivas E; Navarro Mascarell G; Meca Lallana J; Maestre Martínez A; Pérez Sempere Á; Gracia Gil J; Pato Pato A
    Neurologia; 2017; 32(1):29-39. PubMed ID: 25697827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe local skin reactions to interferon beta-1b in multiple sclerosis-improvement by deep subcutaneous injection.
    Nakamura Y; Kawachi Y; Furuta J; Otsuka F
    Eur J Dermatol; 2008; 18(5):579-82. PubMed ID: 18693165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lobular panniculitis at the site of subcutaneous interferon beta injections for the treatment of multiple sclerosis can histologically mimic pancreatic panniculitis. A study of 12 cases.
    Ball NJ; Cowan BJ; Hashimoto SA
    J Cutan Pathol; 2009 Mar; 36(3):331-7. PubMed ID: 19032383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic myeloid leukaemia in two multiple sclerosis patients on interferon beta-1a.
    Almeida L; Neves M; Cardoso E; Melo A
    J Clin Pharm Ther; 2009 Feb; 34(1):125-7. PubMed ID: 19125911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
    Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
    Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time of interferon-beta 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients.
    Kümpfel T; Schwan M; Pollmächer T; Yassouridis A; Uhr M; Trenkwalder C; Weber F
    Mult Scler; 2007 Nov; 13(9):1138-45. PubMed ID: 17967841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study.
    Flechter S; Vardi J; Finkelstein Y; Pollak L
    Isr Med Assoc J; 2007 Jun; 9(6):457-9. PubMed ID: 17642394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new electronic device for subcutaneous injection of IFN-β-1a.
    Exell S; Verdun E; Driebergen R
    Expert Rev Med Devices; 2011 Sep; 8(5):543-53. PubMed ID: 21728909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event.
    Pakdaman H; Sahraian MA; Fallah A; Pakdaman R; Ghareghozli K; Ghafarpour M; Rahimian E; Shirani A
    Acta Neurol Scand; 2007 Jun; 115(6):429-31. PubMed ID: 17511854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population.
    Twork S; Nippert I; Scherer P; Haas J; Pöhlau D; Kugler J
    Curr Med Res Opin; 2007 Jun; 23(6):1209-15. PubMed ID: 17559722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
    Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.